John W Kozarich sold $91k of LGND
director at LIGAND PHARMACEUTICALS INC. 467 shares at an average of $195.91, traded Feb 2, 2026, filed Feb 4, 2026.
Score components
- +15RoleDirector
- +9Trade size$91k at market
- 0Share of holdings soldSold 1.1% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002001011-26-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 2, 2026 | SOpen-market sale Common Stock10b5-1 | -39 | $191.00 | $7,449 | 43,615 | Feb 4, 2026 |
| Feb 2, 2026 | SOpen-market sale Common Stock10b5-1 | -1 | $192.18 | $192 | 43,614 | Feb 4, 2026 |
| Feb 2, 2026 | SOpen-market sale Common Stock10b5-1 | -23 | $195.61 | $4,499 | 43,591 | Feb 4, 2026 |
| Feb 2, 2026 | SOpen-market sale Common Stock10b5-1 | -381 | $196.36 | $75k | 43,210 | Feb 4, 2026 |
| Feb 2, 2026 | SOpen-market sale Common Stock10b5-1 | -23 | $197.20 | $4,535 | 43,187 | Feb 4, 2026 |
Related signals
Other insiders at LIGAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.5M 5,000 shares | -14% | |
| 43Moderate | LIGAND PHARMACEUTICALS INC | Martine Zimmermann director | $342k 1,200 shares | -24% | |
| 33Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.4M 5,000 shares | -12% | |
| 40Moderate | LGNDsell LIGAND PHARMACEUTICALS INC | Jason Aryeh director | $1.3M 5,000 shares | -5% | |
| 32Weak | LIGAND PHARMACEUTICALS INC | John L Lamattina director | $434k 2,161 shares | -7% | |
| 35Weak | LIGAND PHARMACEUTICALS INC | Stephen L Sabba director | $208k 1,000 shares | -3% | |
| 28Weak | LIGAND PHARMACEUTICALS INC | Octavio Espinoza Chief Financial Officer | $688k 3,057 shares | -13% | |
| 37Weak | LIGAND PHARMACEUTICALS INC | Octavio Espinoza Chief Financial Officer | $2.8M 13,423 shares | -38% | |
| 25Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.0M 5,000 shares | -12% | |
| 31Weak | LIGAND PHARMACEUTICALS INC | Stephen L Sabba director | $410k 2,034 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.